Voya Investment Management LLC Acquires 1,884 Shares of Wave Life Sciences Ltd (WVE)

Share on StockTwits

Voya Investment Management LLC lifted its holdings in shares of Wave Life Sciences Ltd (NASDAQ:WVE) by 37.8% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 6,873 shares of the company’s stock after purchasing an additional 1,884 shares during the period. Voya Investment Management LLC’s holdings in Wave Life Sciences were worth $263,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of the company. Janus Henderson Group PLC lifted its holdings in shares of Wave Life Sciences by 11.8% during the second quarter. Janus Henderson Group PLC now owns 1,518,758 shares of the company’s stock worth $58,092,000 after purchasing an additional 160,545 shares during the period. BlackRock Inc. lifted its holdings in shares of Wave Life Sciences by 37.0% during the second quarter. BlackRock Inc. now owns 1,201,655 shares of the company’s stock worth $45,963,000 after purchasing an additional 324,659 shares during the period. BB Biotech AG lifted its holdings in shares of Wave Life Sciences by 27.0% during the second quarter. BB Biotech AG now owns 1,137,885 shares of the company’s stock worth $43,524,000 after purchasing an additional 241,789 shares during the period. FMR LLC lifted its holdings in shares of Wave Life Sciences by 6.1% during the second quarter. FMR LLC now owns 1,036,878 shares of the company’s stock worth $39,661,000 after purchasing an additional 59,879 shares during the period. Finally, Wells Fargo & Company MN lifted its holdings in shares of Wave Life Sciences by 5,257.8% during the second quarter. Wells Fargo & Company MN now owns 360,633 shares of the company’s stock worth $13,794,000 after purchasing an additional 353,902 shares during the period. Institutional investors own 83.42% of the company’s stock.

In other Wave Life Sciences news, insider Chris Francis sold 11,575 shares of Wave Life Sciences stock in a transaction on Tuesday, September 25th. The shares were sold at an average price of $56.00, for a total value of $648,200.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Keith Regnante sold 29,500 shares of Wave Life Sciences stock in a transaction on Monday, September 24th. The shares were sold at an average price of $55.00, for a total transaction of $1,622,500.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 44,075 shares of company stock valued at $2,435,700. Insiders own 44.20% of the company’s stock.

WVE stock opened at $47.58 on Friday. The firm has a market capitalization of $1.43 billion, a P/E ratio of -12.36 and a beta of 1.00. The company has a current ratio of 6.11, a quick ratio of 6.11 and a debt-to-equity ratio of 0.05. Wave Life Sciences Ltd has a 12-month low of $21.20 and a 12-month high of $56.00.

Wave Life Sciences (NASDAQ:WVE) last released its earnings results on Thursday, August 9th. The company reported ($1.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.88). The firm had revenue of $4.88 million during the quarter, compared to analyst estimates of $7.38 million. Wave Life Sciences had a negative net margin of 1,473.26% and a negative return on equity of 91.88%. Equities analysts anticipate that Wave Life Sciences Ltd will post -4.99 earnings per share for the current fiscal year.

WVE has been the topic of several recent analyst reports. BidaskClub lowered shares of Wave Life Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday, September 28th. HC Wainwright set a $49.00 target price on shares of Wave Life Sciences and gave the company a “buy” rating in a report on Friday, August 10th. Mizuho set a $65.00 target price on shares of Wave Life Sciences and gave the company a “buy” rating in a report on Thursday, August 9th. Stifel Nicolaus initiated coverage on shares of Wave Life Sciences in a report on Monday, August 6th. They issued a “buy” rating and a $56.00 target price on the stock. Finally, ValuEngine upgraded shares of Wave Life Sciences from a “buy” rating to a “strong-buy” rating in a report on Monday, July 2nd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $58.40.

Wave Life Sciences Company Profile

Wave Life Sciences Ltd., a biotechnology company, designs, develops, and commercializes nucleic acid therapeutic candidates for genetically defined diseases by utilizing proprietary synthetic chemistry drug development platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins.

Recommended Story: Discount Rate

Institutional Ownership by Quarter for Wave Life Sciences (NASDAQ:WVE)

Receive News & Ratings for Wave Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Wave Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply